Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of cisplatin dose, renal function, and other factors on audiometrically-assessed ototoxicity in more than 1400 adult-onset cancer survivors from The Platinum Study: a multicentre cohort study.

EClinicalMedicine·2026
Same author

Renal Impairment and Late Toxicities Comparing Contemporary Chemotherapy Regimens for Testicular Cancer in a Real-World Setting.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same author

Cardiovascular disease risk among long-term testicular cancer survivors following contemporary cisplatin-based chemotherapy.

Journal of the National Cancer Institute·2026
Same author

CT online adaptive radiotherapy is associated with dosimetric and acute toxicity improvements in prostate cancer treatment.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology·2025
Same author

Stereotactic magnetic resonance imaging-guided adaptive radiotherapy: a pooled analysis of a master prospective trial.

Journal of the National Cancer Institute·2025
Same author

Factors associated with longitudinal progression of the cumulative burden of morbidity and overall mortality after cisplatin-based chemotherapy for testicular cancer.

Journal of the National Cancer Institute·2025

Related Experiment Video

Updated: Mar 24, 2026

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

17.3K

New developments in prostate cancer biomarkers.

Neil E Martin1

  • 1Department of Radiation Oncology, Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts, USA.

Current Opinion in Oncology
|March 15, 2016
PubMed
Summary

Novel molecular biomarkers are improving localized prostate cancer management. Tests like the Genomic Prostate score (GPS) and Cell Cycle Progression score (CCPS) help identify high-risk patients and guide treatment decisions.

More Related Videos

Author Spotlight: Advancing Prostate Cancer Research Through Improved Tissue Sampling and Biobanking
07:34

Author Spotlight: Advancing Prostate Cancer Research Through Improved Tissue Sampling and Biobanking

Published on: November 17, 2023

1.4K
miRNA Expression Analyses in Prostate Cancer Clinical Tissues
11:29

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

Published on: September 8, 2015

11.3K

Related Experiment Videos

Last Updated: Mar 24, 2026

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

17.3K
Author Spotlight: Advancing Prostate Cancer Research Through Improved Tissue Sampling and Biobanking
07:34

Author Spotlight: Advancing Prostate Cancer Research Through Improved Tissue Sampling and Biobanking

Published on: November 17, 2023

1.4K
miRNA Expression Analyses in Prostate Cancer Clinical Tissues
11:29

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

Published on: September 8, 2015

11.3K

Area of Science:

  • Oncology
  • Genetics
  • Urology

Background:

  • Localized prostate cancer management is complex due to numerous prognostic subgroups.
  • Molecular and genetic biomarkers offer potential to aid clinical and patient decision-making.

Purpose of the Study:

  • To review the current landscape of molecular and genetic biomarkers for localized prostate cancer.
  • To assess the utility of these biomarkers in treatment decision-making.

Main Methods:

  • Review of commercially available genomic tests for prostate cancer.
  • Analysis of retrospective and prospective data supporting biomarker use.

Main Results:

  • Genomic Prostate score (GPS), Cell Cycle Progression score (CCPS), and Genomic Classifier show promise in localized prostate cancer.
  • These tests identify men at higher risk for adverse outcomes post-prostatectomy.
  • GPS and CCPS show potential for guiding active surveillance decisions; Genomic Classifier also acts as a predictive marker.

Conclusions:

  • Novel biomarkers are emerging for improved prostate cancer management.
  • Retrospective data show significant promise, but prospective validation is needed to guide clinical practice changes.